Apremilast Study for Behçet's disease

(1:40)

Real world study shows apremilast safe to treat PsO, PsA patients

(1:8)

Psoriatic Arthritis in the Clinic: Treating to Target and Working with Dermatologists

(24:22)

Amylyx's ALS Drug AMX0035 shows promising Phase 2/3 Clinical Trial Results

(58:18)

Report: FDA-approved Otezla can dramatically reduce cravings for alcohol

(1:33)

Update in Treatment of Psoriatic Arthritis

(22:28)

Mark Lebwohl, MD - Apremilast as an Off-Label Therapeutic Agent

(1:57)

WHAT'S NEW : NEWER INDICATIONS FOR APREMILAST

(1:31)

Psoriatic Disease in Women of Childbearing Age

(55:32)

Apremilast (Otezla) and Keratoderma

(1:11)

Behcet's Disease: A Canadian Perspective On Awareness, Treatment And Management

(29:6)

FDA Approves Label Update to Include Additional Data for Otezla ® (apremilast)

(9:49)

Navigating Mechanisms of UC Therapies

(21:59)

The TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option in Moderate to Severe Psoriasis

(37:46)

Psoriasis Treatments: Are pills right for your psoriasis?

(7:50)

Apremilast useful in psoriatic arthritis

(3:13)

Lecture-120: Introduction to Apremilast in Psoriasis

(15:24)

Apremilast [AB0927] (Part 5) - Psoriatic Arthritis Posters and Abstracts from Amsterdam

(7:13)